Bristol Myers Squibb CompanyBMY announced that the FDA has cleared its intravenous human programmed death receptor 1 (PD 1) blocking antibody, Opdivo, for the treatment of patients with metastatic non small cell lung cancer (NSCLC) with progression on or
Bristol-Myers Cancer Drug Opdivo's Label Expanded in U.S.
